Regencell Bioscience Holdings Ltd (RGC, Financial), a company specializing in traditional Chinese medicine for neurological and cognitive disorders, experienced a significant stock price drop of 6.23%. The stock is currently priced at $5.72 per share with a trading volume of 6,025 shares, indicating a turnover rate of 0.05% and a price fluctuation amplitude of 4.10%.
Recent financial reports reveal that Regencell Bioscience has not generated any operating revenue, posting a net loss of $4.30 million and an earnings per share (EPS) of -$0.33. The company also reported a gross profit of -$745,588 and a price-to-earnings (P/E) ratio of -18.12. Currently, there are no institutional ratings available for buy, hold, or sell recommendations for RGC.
Within the broader pharmaceutical industry, the overall growth was 0.37%. Notable performers include Im Cannabis Corp., Procaps Group S.A. C/Wts 29/09/2026 (To Pur Com), and Medicus Pharma Ltd., which showed significant gains. Im Cannabis Corp., Sunshine Biopharma Inc., and Akanda Corp. were particularly active, with turnover rates of 92.03%, 16.08%, and 14.91%, respectively. Stocks with notable price fluctuations included Procaps Group S.A. C/Wts 29/09/2026 (To Pur Com), Im Cannabis Corp., and Biofrontera Inc C/Wts 27/10/2026 (To Pur Com), with amplitudes of 54.75%, 39.34%, and 36.30%, respectively.
